Search Results
Sep 08, 2026, 07:00 ET Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and
More news about: Compugen Ltd.
Sep 08, 2026, 07:00 ET Israel National Biotech Innovation Center (INBI) Announces Official Launch and the Appointment of Anat Cohen-Dayag, PhD, as Chief Executive Officer of INBI Core
advance an exceptional portfolio of promising Israeli biomedical research programs. It will build a world-class team with deep expertise in early-stage drug development, provide the necessary infrastructure and funding and unlock capital and commercialization opportunities for the next generation of Israeli
More news about: Israel National Biotech Innovation Center
Sep 08, 2026, 06:59 ET Carboxymethylcellulose Calcium Market worth $0.09 billion by 2036 - Exclusive Report by MarketsandMarkets™
oral and topical drug formulations, where carboxymethylcellulose calcium helps improve formulation consistency, viscosity, and product stability. In addition, the growing pharmaceutical manufacturing base across emerging economies is creating opportunities for excipient suppliers as drug production and
More news about: MarketsandMarkets
Sep 08, 2026, 06:45 ET New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgical pain studies
of rigorous clinical development behind TYLENOL® with Naproxen, a new, non-opioid, OTC combination pain relief medicine approved by the U.S. Food and Drug Administration (FDA) in July 2026.
More news about: Kenvue Inc.
Sep 08, 2026, 06:30 ET Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving,
More news about: Caris Life Sciences
Sep 08, 2026, 06:10 ET Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
oral tablets (oral amylin receptor peptide agonist) for the treatment of obesity after recently receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
More news about: Ascletis Pharma Inc.
Sep 08, 2026, 06:10 ET 歌禮宣布在美國啟動口服胰澱素受體激動劑多肽ASC36治療肥胖症的I期研究
的口服小分子和長效注射劑項目，ASC36進一步強化了我們的多元化產品管線，以滿足肥胖症及其他代謝疾病患者不斷變化的治療需求。」ASC36是一款利用歌禮專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）技術自主研發的胰澱素受體激動劑多肽。ASC36口服片劑由歌禮利用其專有的口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT）開發並優化而成，該技術用於實現口服多肽遞送。在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7天後，穩態下的絕對口服生物利用度（absolute
More news about: 歌禮製藥有限公司
Sep 08, 2026, 04:17 ET Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgery
advance BAFA into Phase 2b development. "In our short proof-of-concept study aimed at showing an immediate calcium balance-effect of our drug candidate, BAFA produced coherent biological effects on markers of calcium homeostasis," says Dr. Ville Wallenius, MD, PhD, Adjunct Professor
More news about: Epicyt Pharma AB
Sep 08, 2026, 04:05 ET /C O R R E C T I O N -- GCCL/
explored opportunities to expand its clinical sample analysis and assay development services across the Asia-Pacific region.The company engaged with drug developers working across a broad range of therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based
More news about: GCCL
Sep 08, 2026, 02:08 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Sep 07, 2026, 13:46 ET Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Sep 07, 2026, 13:22 ET Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline
CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory
More news about: Hagens Berman Sobol Shapiro LLP
Sep 07, 2026, 11:06 ET Stem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research
is being driven by rising interest in regenerative medicine, wider use of cell-based therapies, and growing reliance on stem cells for drug discovery and biomedical research. An aging population coupled with a heavier burden of chronic and degenerative conditions is pushing healthcare systems
More news about: Wissen Research LLC
Sep 07, 2026, 10:31 ET Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight
11.2.1Drug Description11.2.2
More news about: DelveInsight Business Research, LLP
Sep 07, 2026, 10:15 ET Cold Plasma Market worth $3.03 billion by 2031 - Exclusive Report by MarketsandMarkets™
Wastewater Surveillance Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031About MarketsandMarkets™MarketsandMarkets™
More news about: MarketsandMarkets
Sep 07, 2026, 10:01 ET Laboratory Glassware Market worth $9,170 million by 2031 - Exclusive Report by MarketsandMarkets™
market is driven by increasing applications in clinical use, pharmaceutical and drug-discovery research, veterinary science, agriculture, biology, and biotechnology. The growing prevalence of chronic diseases has supported new drug development, while increasing research in vaccine development, disease research,
More news about: MarketsandMarkets
Sep 07, 2026, 08:00 ET Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
biopharmaceuticals.In addition, at a bilateral meeting with Indonesian Food and Drug Authority (BPOM), the two sides discussed cooperation on the stable supply of source plasma and, building on regulatory trust in the field of drug approval and review, Korea proposed being registered as a reference country
More news about: The Korea Herald
Sep 07, 2026, 06:59 ET Thermoplastic Polyimide Market worth $0.86 billion in 2032 - Exclusive Report by MarketsandMarkets™
Plastics, Engineering Plastics, High-performance Plastics), Application (Medical Disposables, Medical Instruments & Devices, Prosthetics & Implants, Drug Delivery, Medical Packaging) - Global Forecast to 2031
More news about: MarketsandMarkets
Sep 07, 2026, 06:00 ET Best Minoxidil for Women (2026): Happy Head Recognized for Personalized Minoxidil Formulas by Consumer365
dutasteride, finasteride, or other ingredients when prescribed. Oral plans may place minoxidil in one capsule with other medicines or use a non-minoxidil drug such as spironolactone.Because delivery route, dose, and active ingredients can affect side effects and suitability, a licensed clinician must
More news about: Consumer365.org
Sep 07, 2026, 06:00 ET The 25th Anniversary of the Day that Changed America: 9/11 and the Facts, the Theories and the Conspiracies
to the Mob. Unreported stories including the assassination attempt on President George W. Bush on the morning of September 11, 2001, and the rampant drug trafficking of the flight school financier are fully discussed, with attention to the stunning evidence of the CIA's knowledge that hundreds of Arab
More news about: TrineDay Books
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
represents the first clinical evaluation of a potentially first-in-class drug candidate featuring both an AI-discovered target with relevance to aging and disease biology and an AI-designed molecule, rather than a repurposed generic drug such as rapamycin or metformin. The findings also provide a proof-of-concept
More news about: Insilico Medicine
Sep 07, 2026, 00:15 ET 歌禮宣佈獲納入滬港通及深港通計劃項下的港股通名單
一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥
More news about: 歌禮製藥有限公司
Sep 07, 2026, 00:15 ET Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides,
More news about: Ascletis Pharma Inc.
Sep 06, 2026, 20:01 ET Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
resources and flexibility to support its strategic execution.In terms of the pipeline, the Company has built a portfolio of nearly 30 differentiated drug candidates across multiple therapeutic areas, including immunology, oncology, metabolism, and the central nervous system (CNS), with several molecules
More news about: Harbour BioMed
Sep 05, 2026, 08:57 ET Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials
challenges. As part of the planned commercialization framework, the companies intend Signant to serve as the exclusive provider of ALDS PRO for drug trial applications. Signant and Lothar Medical will work together on the scientific, technical, operational, and commercial activities required to prepare
More news about: Signant Health